Department of Burns, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China.
World J Gastroenterol. 2024 Sep 21;30(35):3932-3941. doi: 10.3748/wjg.v30.i35.3932.
In this editorial, we comment on an article published in the recent issue of the . Celiac disease (CeD) is a disease occurring in genetically susceptible individuals, which is mainly characterized by gluten intolerance in the small intestine and clinical symptoms such as abdominal pain, diarrhea, and malnutrition. Therefore, patients often need a lifelong gluten-free diet, which greatly affects the quality of life and expenses of patients. The gold standard for diagnosis is intestinal mucosal biopsy, combined with serological and genetic tests. At present, the lack of safe, effective, and satisfactory drugs for CeD is mainly due to the complexity of its pathogenesis, and it is difficult to find a perfect target to solve the multi-level needs of patients. In this editorial, we mainly review the pathological mechanism of CeD and describe the current experimental and improved drugs for various pathological aspects.
在这篇社论中，我们对近期发表在《》上的一篇文章进行了评论。乳糜泻（CeD）是一种发生在遗传易感个体中的疾病，主要表现为小肠对麸质不耐受和腹痛、腹泻、营养不良等临床症状。因此，患者通常需要终生无麸质饮食，这极大地影响了患者的生活质量和费用。诊断的金标准是肠黏膜活检，结合血清学和遗传学检查。目前，CeD 缺乏安全、有效和令人满意的药物，主要是由于其发病机制复杂，难以找到一个完美的靶点来解决患者多层次的需求。在这篇社论中，我们主要综述了 CeD 的病理机制，并描述了目前针对各种病理方面的实验和改良药物。
